Thyrotropin

Summary

Thyrotropin (CHEMBL1201532) is an approved unknown (ATC V04CJ01) targeting TSHR; indicated across 3 conditions including head and neck cancer and thyroid gland follicular carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: V04CJ01
• Targets: 1 (TSHR)
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201532
Name	Thyrotropin
Type	Unknown
Max phase	4
ATC	V04CJ01

Also known as: Thyrotrophin, Thyrotrophine, Thyrotropin, Thyrotropin (bovine), Thytropar, Tirotrofina, THYROTROPIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TSHR	TSH receptor	Agonist		0%	P16473

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TSHR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hormone ligand-binding receptors	1	TSHR
G alpha (s) signalling events	1	TSHR

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	1
G protein-coupled receptor signaling pathway	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
cell-cell signaling	1
positive regulation of cell population proliferation	1
hormone-mediated signaling pathway	1
thyroid-stimulating hormone signaling pathway	1
positive regulation of cold-induced thermogenesis	1
cellular response to glycoprotein	1
cellular response to thyrotropin-releasing hormone	1
signal transduction	1
response to hormone	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
head and neck cancer	3	MONDO:0005627	EFO:0006859
thyroid gland follicular carcinoma	2	MONDO:0005034	EFO:0000501
thyroid gland papillary carcinoma	2	MONDO:0005075	EFO:0000641

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

340 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ACETAMINOPHEN	ChEMBL	Phase 4 (approved)	TSHR
ACETOHEXAMIDE	ChEMBL	Phase 4 (approved)	TSHR
ACYCLOVIR	ChEMBL	Phase 4 (approved)	TSHR
ALCOHOL	ChEMBL	Phase 4 (approved)	TSHR
ALLOPURINOL	ChEMBL	Phase 4 (approved)	TSHR
AMANTADINE	ChEMBL	Phase 4 (approved)	TSHR
AMILORIDE	ChEMBL	Phase 4 (approved)	TSHR
AMINOPYRINE	ChEMBL	Phase 4 (approved)	TSHR
AMIODARONE	ChEMBL	Phase 4 (approved)	TSHR
AMISULPRIDE	ChEMBL	Phase 4 (approved)	TSHR
AMOXAPINE	ChEMBL	Phase 4 (approved)	TSHR
AMSACRINE	ChEMBL	Phase 4 (approved)	TSHR
ANTAZOLINE	ChEMBL	Phase 4 (approved)	TSHR
APRACLONIDINE	ChEMBL	Phase 4 (approved)	TSHR
ASPIRIN	ChEMBL	Phase 4 (approved)	TSHR
ATOMOXETINE	ChEMBL	Phase 4 (approved)	TSHR
AZELAIC ACID	ChEMBL	Phase 4 (approved)	TSHR
AZITHROMYCIN	ChEMBL	Phase 4 (approved)	TSHR
BENOXINATE	ChEMBL	Phase 4 (approved)	TSHR
BENZBROMARONE	ChEMBL	Phase 4 (approved)	TSHR
BENZTHIAZIDE	ChEMBL	Phase 4 (approved)	TSHR
BENZYL ALCOHOL	ChEMBL	Phase 4 (approved)	TSHR
BERBERINE	ChEMBL	Phase 4 (approved)	TSHR
BETAINE	ChEMBL	Phase 4 (approved)	TSHR
BISACODYL	ChEMBL	Phase 4 (approved)	TSHR
BITHIONOL	ChEMBL	Phase 4 (approved)	TSHR
BUMETANIDE	ChEMBL	Phase 4 (approved)	TSHR
BUSULFAN	ChEMBL	Phase 4 (approved)	TSHR
BUTAMBEN	ChEMBL	Phase 4 (approved)	TSHR
CARBAMAZEPINE	ChEMBL	Phase 4 (approved)	TSHR
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	TSHR
CARBETAPENTANE	ChEMBL	Phase 4 (approved)	TSHR
CARISOPRODOL	ChEMBL	Phase 4 (approved)	TSHR
CARMUSTINE	ChEMBL	Phase 4 (approved)	TSHR
CELECOXIB	ChEMBL	Phase 4 (approved)	TSHR
CHLORAMBUCIL	ChEMBL	Phase 4 (approved)	TSHR
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	TSHR
CHLOROTHIAZIDE	ChEMBL	Phase 4 (approved)	TSHR
CHLOROTRIANISENE	ChEMBL	Phase 4 (approved)	TSHR
CHLORPROPAMIDE	ChEMBL	Phase 4 (approved)	TSHR
CHLORZOXAZONE	ChEMBL	Phase 4 (approved)	TSHR
CILOSTAZOL	ChEMBL	Phase 4 (approved)	TSHR
CIMETIDINE	ChEMBL	Phase 4 (approved)	TSHR
CINOXACIN	ChEMBL	Phase 4 (approved)	TSHR
CLEMASTINE	ChEMBL	Phase 4 (approved)	TSHR
CLOFIBRATE	ChEMBL	Phase 4 (approved)	TSHR
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	TSHR
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	TSHR
CLOZAPINE	ChEMBL	Phase 4 (approved)	TSHR
COLCHICINE	ChEMBL	Phase 4 (approved)	TSHR
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	TSHR
CYCLOSERINE	ChEMBL	Phase 4 (approved)	TSHR
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	TSHR
CYSTEAMINE	ChEMBL	Phase 4 (approved)	TSHR
DACARBAZINE	ChEMBL	Phase 4 (approved)	TSHR
DALFAMPRIDINE	ChEMBL	Phase 4 (approved)	TSHR
DANTHRON	ChEMBL	Phase 4 (approved)	TSHR
DAPSONE	ChEMBL	Phase 4 (approved)	TSHR
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	TSHR
DEBRISOQUIN	ChEMBL	Phase 4 (approved)	TSHR